Veracyte
Developer and operator of laboratory-based molecular diagnostics and an integrated genomics platform focused on cancer. The company performs broad molecular profiling (genomic and transcriptomic), develops and validates diagnostic assays, applies AI/bioinformatics to large curated genomic databases, and supports clinical studies and reimbursement efforts to inform cancer care decisions across multiple tumor types.
Industries
Nr. of Employees
large (251-1000)
Veracyte
South San Francisco, California, United States, North America
Patents
Methods for classification of tissue samples as positive or negative for cancer
US-12297503-B2
View DetailsMethods for classification of tissue samples as positive or negative for cancer
US-12110554-B2
View Details
Methods for classification of tissue samples as positive or negative for cancer
US-12297503-B2
View DetailsMethods for classification of tissue samples as positive or negative for cancer
US-12110554-B2
View DetailsProducts
Genomic diagnostic tests for thyroid, prostate, breast, bladder and lung cancers
A portfolio of laboratory-based molecular diagnostic tests that assess tumor biology to inform diagnosis, prognosis, treatment selection, and monitoring across multiple cancer types.
Genomic diagnostic tests for thyroid, prostate, breast, bladder and lung cancers
A portfolio of laboratory-based molecular diagnostic tests that assess tumor biology to inform diagnosis, prognosis, treatment selection, and monitoring across multiple cancer types.
Services
Clinical laboratory services providing broad genomic and transcriptomic profiling and diagnostic reports to clinicians for cancer management.
Clinical laboratory services providing broad genomic and transcriptomic profiling and diagnostic reports to clinicians for cancer management.
Expertise Areas
- Molecular diagnostics development
- Biomarker discovery and validation
- Bioinformatics and AI for genomics
- ctDNA-based MRD monitoring
Key Technologies
- Whole-transcriptome sequencing (RNA-seq)
- Whole-genome sequencing (WGS)
- Circulating tumor DNA (ctDNA) profiling
- Next-generation sequencing (NGS) assays
News & Updates
Presentations and poster sessions involving clinical and biomarker studies integrating transcriptome and genomic classifiers, and MRD/biomarker strategy content.
Publication and presentation of trial results supporting use of a transcriptome-based test to identify patients who may avoid chemotherapy in breast cancer.
Payer coverage milestone for a tumor-informed MRD monitoring test, supporting clinical access and reimbursement.
Commercial availability in the U.S. for a breast cancer recurrence-risk genomic test (launched May/June 2026).
Presentations and poster sessions involving clinical and biomarker studies integrating transcriptome and genomic classifiers, and MRD/biomarker strategy content.
Publication and presentation of trial results supporting use of a transcriptome-based test to identify patients who may avoid chemotherapy in breast cancer.
Payer coverage milestone for a tumor-informed MRD monitoring test, supporting clinical access and reimbursement.
Commercial availability in the U.S. for a breast cancer recurrence-risk genomic test (launched May/June 2026).